SCHEMBL1683807

SCHEMBL1683807

COc1cc(C(=O)c2cscn2)cc(OC)c1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ECE1 P42892 1/20 0.51
▸ TUBB4A P04350 6/20 0.49
▸ TUBB P07437 6/20 0.49
▸ TUBA3C P0DPH7 6/20 0.49
▸ TUBA1B P68363 6/20 0.49
▸ TUBA4A P68366 6/20 0.49
▸ TUBB4B P68371 6/20 0.49
▸ TUBB3 Q13509 6/20 0.49
▸ TUBB2A Q13885 6/20 0.49
▸ TUBB8 Q3ZCM7 6/20 0.49
▸ TUBA3E Q6PEY2 6/20 0.49
▸ TUBA1A Q71U36 6/20 0.49
▸ TUBA1C Q9BQE3 6/20 0.49
▸ TUBB6 Q9BUF5 6/20 0.49
▸ TUBB2B Q9BVA1 6/20 0.49
▸ TUBB1 Q9H4B7 6/20 0.49
▸ EGFR P00533 1/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ BRD4 O60885 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4819729 0.76 TUBB4A (0.75) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL786898 0.75 EGFR (0.55) ECE1TUBB4ATUBBTUBA3CTUBA1B
Hydrochloric Acid SCHEMBL27888195 0.74 TUBB4A (0.72) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL23904562 0.74 CNR2 (0.58) SMN1; SMN2RAB9AMAPT
SCHEMBL1683629 0.74 EGFR (0.69) EGFRHDAC3HDAC1HDAC7HDAC8
SCHEMBL1683786 0.73 TUBB1 (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1683776 0.72 EGFR (0.58) EGFRHDAC3HDAC1HDAC7HDAC8
SCHEMBL4532908 0.72 KDM4E (0.67) ECE1HDAC3HDAC1
Hydrochloric Acid SCHEMBL26634476 0.72 TUBB1 (0.48) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL28117690 0.71 MEN1 (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3289876-B1 COMPOUNDS FOR TREATMENT OF CANCER UNIV TENNESSEE RES FOUND (US) 2022-07-20 — — EP disclosed
US-10865196-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2020-12-15 — — US disclosed
US-10865196-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2020-12-15 — — US disclosed
US-10301285-B2 Compounds for treatment of cancer GTX, INC. (US) 2019-05-28 — — US disclosed
US-10301285-B2 Compounds for treatment of cancer GTX, INC. (US) 2019-05-28 — — US disclosed
US-20190092755-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2019-03-28 — — US disclosed
US-20190092755-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2019-03-28 — — US disclosed
US-20180093971-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2018-04-05 — — US disclosed
US-20180093971-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2018-04-05 — — US disclosed
US-20180093971-A1 COMPOUNDS FOR TREATMENT OF CANCER ONCTERNAL THERAPEUTICS, INC 2018-04-05 — — US disclosed
US-9029408-B2 Compounds for treatment of cancer GTX, INC. (US) 2015-05-12 — — US disclosed
US-9029408-B2 Compounds for treatment of cancer GTX, INC. (US) 2015-05-12 — — US disclosed
US-20140213623-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2014-07-31 — — US disclosed
US-20140213623-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2014-07-31 — — US disclosed
US-20140213623-A1 COMPOUNDS FOR TREATMENT OF CANCER GTX, INC. (US) 2014-07-31 — — US disclosed
US-8592465-B2 Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2013-11-26 — — US disclosed
EP-2303021-A2 COMPOUNDS FOR THE TREATMENT OF CANCER University of Tennessee Research Foundation (US) 2011-04-06 — — EP disclosed
WO-2010074776-A2 COMPOUNDS FOR THE TREATMENT OF CANCER THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-07-01 — — WO disclosed
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2009-12-31 — — US disclosed
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326020-A1 COMPOUNDS FOR TREATMENT OF CANCER HCCS, NQO1, CCNY ECE1 1517/4885TUBB4A 2060/4885TUBB 2030/4885
US-10865196-B2 Compounds for treatment of cancer CYP19A1, CYP17A1, SOX18 ECE1 3916/4885TUBB4A 237/4885TUBB 461/4885
US-10301285-B2 Compounds for treatment of cancer CYP19A1, CYP17A1, SOX18 ECE1 3916/4885TUBB4A 237/4885TUBB 461/4885
US-20140213623-A1 COMPOUNDS FOR TREATMENT OF CANCER CYP19A1, CYP17A1, SOX18 ECE1 3916/4885TUBB4A 237/4885TUBB 461/4885
US-20180093971-A1 COMPOUNDS FOR TREATMENT OF CANCER CYP19A1, CYP17A1, SOX18 ECE1 3916/4885TUBB4A 237/4885TUBB 461/4885
US-20190092755-A1 COMPOUNDS FOR TREATMENT OF CANCER CYP19A1, CYP17A1, SOX18 ECE1 3916/4885TUBB4A 237/4885TUBB 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback